Disease ยท HP_0001945
Fever
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Fever. Diseases, record HP_0001945. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0001945
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Highest stage of its drugs
- Approval, for 50 of its 125 drugs, from ATC, DailyMed, PMDA and TTD
- Open Targets
Drugs125
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ACETAMINOPHEN | CHEMBL112 | Small molecule | Approval | ATC, DailyMed and PMDA | 67 | 18 | 18 | Drugs and targets |
| IBUPROFEN | CHEMBL521 | Small molecule | Approval | DailyMed | 24 | 16 | 16 | Drugs and targets |
| DIPYRONE | CHEMBL3989803 | Small molecule | Approval | ATC | 4 | 1 | 1 | Drugs and targets |
| DANTROLENE | CHEMBL1201288 | Small molecule | Approval | TTD | 2 | 1 | 1 | Drugs and targets |
| DEXTROMETHORPHAN HYDROBROMIDE | CHEMBL1256818 | Small molecule | Approval | DailyMed | 33 | 0 | 0 | Drugs and targets |
| PHENYLEPHRINE HYDROCHLORIDE | CHEMBL1200339 | Small molecule | Approval | DailyMed | 21 | 0 | 0 | Drugs and targets |
| GUAIFENESIN | CHEMBL980 | Small molecule | Approval | DailyMed | 16 | 0 | 0 | Drugs and targets |
| ASPIRIN | CHEMBL25 | Small molecule | Approval | ATC and DailyMed | 10 | 0 | 0 | Drugs and targets |
| AMINOPYRINE | CHEMBL288470 | Small molecule | Approval | ATC | 3 | 0 | 0 | Drugs and targets |
| ANTIPYRINE | CHEMBL277474 | Small molecule | Approval | ATC | 3 | 0 | 0 | Drugs and targets |
1 to 10 of 125
See all 125 drugsTargets61
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PTGS1 | Cyclooxygenase | 13 | Cyclooxygenase inhibitor; Cyclooxygenase-1 inhibitor | Approval | https://conductscience.org/library/genes/5742 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 12 | Cyclooxygenase inhibitor | Approval | https://conductscience.org/library/genes/5743 | Drugs and targets |
| HRH1 | Histamine H1 receptor | 4 | Histamine H1 receptor antagonist | Approval | https://conductscience.org/library/genes/3269 | Drugs and targets |
| RYR1 | Ryanodine receptor 1 | 2 | Ryanodine receptor 1 antagonist | Approval | https://conductscience.org/library/genes/6261 | Drugs and targets |
| RYR3 | Ryanodine receptor 3 | 2 | Ryanodine receptor 3 antagonist | Approval | https://conductscience.org/library/genes/6263 | Drugs and targets |
| SLC6A2 | Sodium-dependent noradrenaline transporter | 2 | Norepinephrine transporter inhibitor; Norepinephrine transporter releasing agent | Approval | https://conductscience.org/library/genes/6530 | Drugs and targets |
| TNF | Tumor necrosis factor | 2 | TNF-alpha inhibitor | Phase 3 | https://conductscience.org/library/genes/7124 | Drugs and targets |
| TOP1 | DNA topoisomerase 1 | 2 | DNA topoisomerase I inhibitor | Phase 2 | https://conductscience.org/library/genes/7150 | Drugs and targets |
| TOP2A | DNA topoisomerase 2-alpha | 2 | DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor | Phase 2 | https://conductscience.org/library/genes/7153 | Drugs and targets |
| ADRA1A | Adrenergic receptor alpha-1 | 1 | Adrenergic receptor alpha-1 agonist | Approval | https://conductscience.org/library/genes/148 | Drugs and targets |
1 to 10 of 61
See all 61 targetsTrials81
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00598559 | Safety and Efficacy of Intravenous Acetaminophen (IV APAP) in Adult Inpatients | Phase 3 | 213 | 2010-12-10 | Acute Pain, Fever | ACETAMINOPHEN | Its record names the disease | ClinicalTrials.gov |
| NCT00841789 | A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease | Phase 2 | 205 | 2023-05-06 | Mucocutaneous Lymph Node Syndrome, Kawasaki Disease | ETANERCEPT | Its record names the disease | ClinicalTrials.gov |
| NCT01021683 | The Relationship of Defeverscence and Itraconazole Plasma Level Study in Immunocompromised Participants | 203 | 2013-07-03 | Hematologic Neoplasms, Neutropenia, Fever | ITRACONAZOLE | Its record names the disease | ClinicalTrials.gov | |
| NCT00889863 | Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) | Phase 3 | 177 | 2012-10-16 | Systemic Juvenile Idiopathic Arthritis With Active Flare | CANAKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01334944 | Surveillance Trial to Evaluate a Shortened Infusion Time of Intravenous Ibuprofen | Phase 4 | 150 | 2014-06-23 | Pain, Fever | IBUPROFEN | Its record names the disease | ClinicalTrials.gov |
| NCT00150345 | Immediate vs. Deferred Empirical Antifungal Treatment With Voriconazole In Neutropenic Patients | Phase 3 | 147 | 2010-08-18 | Possible Fungal Infection | VORICONAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT01002573 | Safety, Efficacy, and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients | Phase 3 | 118 | 2016-11-07 | Fever | ACETAMINOPHEN, IBUPROFEN | Its record names the disease | ClinicalTrials.gov |
| NCT00564629 | Study of the Efficacy and Safety of Intravenous vs Oral Acetaminophen for Treatment of Fever in Healthy Adult Males | Phase 3 | 105 | 2010-09-21 | Fever | ACETAMINOPHEN | Its record names the disease | ClinicalTrials.gov |
| NCT03065244 | KIDCARE (Kawasaki Disease Comparative Effectiveness Trial) | Phase 3 | 105 | 2021-12-03 | Mucocutaneous Lymph Node Syndrome | INFLIXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00598702 | Study of the Safety & Efficacy of Intravenous Acetaminophen in Pediatric Inpatients | Phase 3 | 100 | 2011-01-06 | Pain, Fever | ACETAMINOPHEN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 81
See all 81 trialsComparisons in its trials48
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm 1 -Etanercept vs ARM 2 Placebo: Determine if Etanercept Treatment Alters the Rate of Coronary Artery Dilation and Disease (CAD) at 2 and 6 Weeks After Treatment in Patients With Dilated Coro | 56 of 100 | 53 of 101 | 201 | NCT00841789 | Trial comparisons |
| Arm 1 -Etanercept vs ARM 2 Placebo: IVIG Refractory | 13 of 100 | 22 of 101 | 201 | NCT00841789 | Trial comparisons |
| Arm 1 -Etanercept vs Arm -2 Placebo: deaths from any cause | 0 of 99 | 0 of 102 | 201 | NCT00841789 | Trial comparisons |
| Arm 1 -Etanercept vs Arm -2 Placebo: serious adverse events | 9 of 99 | 10 of 102 | 201 | NCT00841789 | Trial comparisons |
| Fever vs Pain: serious adverse events | 0 of 11 | 1 of 139 | 150 | NCT01334944 | Trial comparisons |
| Immediate Voriconazole vs Deferred Voriconazole Treatment: serious adverse events | 8 of 81 | 8 of 66 | 147 | NCT00150345 | Trial comparisons |
| Immediate Voriconazole vs Deferred Voriconazole Treatment: Number of Participants Assessed as Needing Further Antineoplastic Therapy as Planned | 42 of 68 | 32 of 54 | 122 | NCT00150345 | Trial comparisons |
| Immediate Voriconazole vs Deferred Voriconazole Treatment: Number of Participants With Defervescence Day 5 (4 Days After Initiation of Study Treatment) | 32 of 68 | 28 of 54 | 122 | NCT00150345 | Trial comparisons |
| Oral Acetaminophen (PO APAP) 1 g vs Intravenous Acetaminophen (IV APAP) 1 g / 100 ml Solution: serious adverse events | 0 of 51 | 0 of 54 | 105 | NCT00564629 | Trial comparisons |
| IVIG vs Infliximab: Number of Participants With IVIG and Infliximab Infusion Reactions and Complications | 1 of 49 | 2 of 54 | 103 | NCT03065244 | Trial comparisons |
1 to 10 of 48
See all 48 comparisons in its trialsPapers from its trials36
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0001945
GET https://conductscience.org/api/diseases/v1/HP_0001945/drugs?page=2